The Interaction of Stroke Risk Factors, Clinical Outcomes and Matrix Metalloproteinase 9 Levels with the Reduction of Vascular Endothelial Growth Factor A Levels at the Incidence of Brain Edema in Acute Ischemic Stroke Patients

Cervical cancer (CC) remains a major diagnostic problem. The introduction of human papillomavirus vaccination significantly reduced the number of new cases; however, the search for new methods that would earlier indicate the development of cancerous changes is vital. The aim of this study was to investigate the diagnostic power of those parameters in comparison to Cancer Antigen 125 (CA 125) and Squamous Cell Carcinoma Antigen (SCC-Ag) in patients with CC and in relation to the control group. The study included 100 patients with CC and 50 healthy women. Plasma levels of tested parameters were determined by enzyme-linked immunosorbent assay, CA 125, and SCC-Ag by chemiluminescent microparticle immunoassay. Plasma levels of all parameters in the total cancer group showed statistical significance (in all cases P < .05). In stage I cancer, only vascular endothelial growth factor (VEGF) and tissue inhibitors of metalloproteinase 1; in stage II, all the tested parameters and CA 125; and in stage III + IV, VEGF, matrix metalloproteinase 9 (MMP-9), and CA 125 showed statistical significance when compared to the healthy volunteers group. Vascular endothelial growth factor showed the highest value of sensitivity from all tested parameters (I: 75%, II: 76%, III + IV: 94%, and 82% in total CC group). The highest specificity was obtained by MMP-9 (94%). In the total CC, stage I, and stage II groups, all tested parameters showed statistically significant area under the receiver operating characteristics curve (AUC), but maximum range was obtained for the combination VEGF + SCC-Ag (I: 0.9146, II: 0.8941, III + IV: 0.9139, total CC group: 0.9347). The combined analysis of tested parameters and tumor markers resulted in an increase in sensitivity and AUC values, which provides hope for developing new panel of biomarkers that may be used in the diagnosis of CC in the future.

Download Full-text

Knockdown of Nrf2 inhibits angiogenesis by downregulating VEGF expression through PI3K/Akt signaling pathway in cerebral microvascular endothelial cells under hypoxic conditions

Biochemistry and Cell Biology ◽

10.1139/bcb-2017-0291 ◽

2018 ◽

Vol 96 (4) ◽

pp. 475-482 ◽

Cited By ~ 17

Author(s):

Yujing Huang ◽

Ying Mao ◽

Huiying Li ◽

Guangxun Shen ◽

Guangxian Nan

Keyword(s):

Vascular Endothelial Growth Factor ◽

Ischemic Stroke ◽

Growth Factor ◽

Signaling Pathway ◽

Akt Signaling ◽

Tube Formation ◽

Vascular Endothelial ◽

Akt Signaling Pathway ◽

Microvascular Endothelial ◽

Endothelial Growth Factor

Ischemic stroke is a major cerebrovascular disease resulting from a transient or permanent local reduction of cerebral blood flow. Angiogenesis plays an important role in cerebral microvascular repair after ischemic stroke. This study aimed at investigating the effect of NF-E2-related factor 2 (Nrf2) on the angiogenesis of mouse cerebral microvascular endothelial bEnd.3 cells in a hypoxic environment. We found that Nrf2 expression was temporarily increased in hypoxia-induced bEnd.3 cells. Knockdown of Nrf2 inhibited the proliferation, migration, as well as tube formation in hypoxia-induced bEnd.3 cells. Meanwhile, vascular endothelial growth factor and PI3K/Akt signaling pathways were identified to be regulated by Nrf2 in hypoxia-induced bEnd.3 cells. It was found that silencing of Nrf2 downregulated the expression levels of NAD(P)H:quinine oxidoreductase-1, vascular endothelial growth factor, p-Akt, and heme oxygenase-1 in hypoxia-induced bEnd.3 cells. Data suggested that hypoxia induced the transient increase of Nrf2, which plays a key role in the angiogenesis of cerebral microangiogenesis, and that Nrf2 regulates the proliferation, migration, as well as tube formation likely through PI3K/Akt signaling pathway in hypoxia-induced bEnd.3 cells. Our study provides proof of concept for the modulation of Nrf2, so as to tilt the balance toward angiogenesis, representing a therapeutic strategy for hypoxia or ischemia disorders such as stroke.

Download Full-text

The Role of Serum Vascular Endothelial Growth Factor and Matrix Metalloproteinase-9 in Predicting Response to Chemotherapy in Patients with Advanced Nonsmall Cell Lung Cancer

Southern Medical Journal ◽

10.1097/smj.0b013e318164e432 ◽

2008 ◽

Vol 101 (3) ◽

pp. 327-328 ◽

Cited By ~ 1

Author(s):

Aziz Yazar ◽

Hilal Soydinc ◽

Esra Ertan ◽

Vildan Yasasever ◽

Faruk Tas

Keyword(s):

Lung Cancer ◽

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Matrix Metalloproteinase ◽

Nonsmall Cell Lung Cancer ◽

Vascular Endothelial ◽

Response To Chemotherapy ◽

Endothelial Growth Factor ◽

Metalloproteinase 9

Download Full-text

Incidence and Risk Factors for Tractional Macular Detachment after Anti-Vascular Endothelial Growth Factor Agent Pretreatment before Vitrectomy for Complicated Proliferative Diabetic Retinopathy

Journal of Clinical Medicine ◽

10.3390/jcm8111960 ◽

2019 ◽

Vol 8 (11) ◽

pp. 1960

Author(s):

Andrea Russo ◽

Antonio Longo ◽

Teresio Avitabile ◽

Vincenza Bonfiglio ◽

Matteo Fallico ◽

...

Keyword(s):

Risk Factors ◽

Vascular Endothelial Growth Factor ◽

Diabetic Retinopathy ◽

Growth Factor ◽

Proliferative Diabetic Retinopathy ◽

Vitreous Hemorrhage ◽

Vascular Endothelial ◽

Macular Detachment ◽

Anti Vegf ◽

Endothelial Growth Factor

The study’s purpose was to determine the incidence, risk factors, and outcomes of tractional macular detachment after anti-vascular endothelial growth factor (VEGF) pretreatment before vitrectomy for complicated proliferative diabetic retinopathy. Patients who underwent primary vitrectomy for complicated proliferative diabetic retinopathy, from January 2012 to 31 December 2018, were enrolled. Ophthalmic and pre-operative data were extracted from electronic record systems. All eyes with a valuable Optical Coherence Tomography (OCT)performed within 5 days before injection of anti-VEGF and on the day of vitrectomy were included. Multivariable logistic regression showed that significant risk factors for developing tractional macular detachment included days between anti-VEGF and vitrectomy (OR, 0.71 [95% CI 0.65–0.76]; p < 0.001), vitreous hemorrhage (OR, 0.23 [95% CI 0.11–0.49]; p < 0.001), and age (OR, 1.05 [95% CI 1.02–1.08]; p < 0.001). Decision-tree analysis showed that the stronger predictors of tractional macular detachment were the time between anti-VEGF injection and vitrectomy (p < 0.001). Secondary predictors were the presence of vitreous hemorrhage (p = 0.012) in eyes that underwent vitrectomy between 6 and 10 days after anti-VEGF injection and younger age (p = 0.031) in eyes that underwent vitrectomy 10 days after anti-VEGF injection. Tractional macular detachment occurs in 10% of eyes after anti-VEGF injection, the main risk factors being days between anti-VEGF injection and vitrectomy, vitreous hemorrhage, and age.

Download Full-text